Chunfang Hao

499 total citations
35 papers, 286 citations indexed

About

Chunfang Hao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Chunfang Hao has authored 35 papers receiving a total of 286 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Chunfang Hao's work include Advanced Breast Cancer Therapies (12 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (8 papers). Chunfang Hao is often cited by papers focused on Advanced Breast Cancer Therapies (12 papers), Cancer Treatment and Pharmacology (9 papers) and HER2/EGFR in Cancer Research (8 papers). Chunfang Hao collaborates with scholars based in China and United States. Chunfang Hao's co-authors include Sen Wei, Xin Li, Honglin Zhao, Jun Chen, Qinghua Zhou, Zhongsheng Tong, Yiran Wei, Cuifen Huang, Xiangyang Xie and Jie Zhang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Chunfang Hao

31 papers receiving 284 citations

Peers

Chunfang Hao
Beige Zong China
Bastianina Canu Italy
Eirini Biziota Greece
Alexander N. Gorelick United States
Huanlei Wu China
Tomasz Tyszkiewicz Poland
Hengyu Lu United States
Ben Staal United States
Woody Han United States
Dionysis Papadatos-Pastos United Kingdom
Beige Zong China
Chunfang Hao
Citations per year, relative to Chunfang Hao Chunfang Hao (= 1×) peers Beige Zong

Countries citing papers authored by Chunfang Hao

Since Specialization
Citations

This map shows the geographic impact of Chunfang Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunfang Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunfang Hao more than expected).

Fields of papers citing papers by Chunfang Hao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunfang Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunfang Hao. The network helps show where Chunfang Hao may publish in the future.

Co-authorship network of co-authors of Chunfang Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Chunfang Hao. A scholar is included among the top collaborators of Chunfang Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chunfang Hao. Chunfang Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hao, Chunfang, Jing Shi, Yuhua Song, et al.. (2025). Dalpiciclib plus fulvestrant and pyrotinib in HR+/HER2-low advanced breast cancer after progression on CDK4/6 inhibition (DapPLE-HER): a Bayesian optimal phase II study. International Journal of Surgery. 111(12). 9210–9218. 1 indexed citations
2.
3.
Hao, Chunfang, et al.. (2024). PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treatment Reviews. 132. 102861–102861. 19 indexed citations
4.
Wang, Kun, Jin Yang, Biyun Wang, et al.. (2024). Expert consensus on the clinical application of immunotherapy in breast cancer: 2024. PubMed. 5. 9–9. 2 indexed citations
5.
Li, Jianbin, Chunfang Hao, Kun Wang, et al.. (2024). Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024. PubMed. 5. 18–18. 19 indexed citations
6.
Gao, Hongfei, Min Yan, Qianjun Chen, et al.. (2023). Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China. Cancers. 15(17). 4360–4360. 2 indexed citations
7.
Zhang, Yunmeng, Zhipeng Wang, Huan Wang, et al.. (2023). Comparisons of clinical characteristics, prognosis, epidemiological factors, and genetic susceptibility between HER2‐low and HER2‐zero breast cancer among Chinese females. Cancer Medicine. 12(14). 14937–14948. 9 indexed citations
8.
Yan, Min, Quchang Ouyang, Tao Sun, et al.. (2023). Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial.. Journal of Clinical Oncology. 41(16_suppl). 1048–1048. 1 indexed citations
9.
Hao, Chunfang, Shilong Chu, Xiongzhi Quan, et al.. (2023). Establishing extended pluripotent stem cells from human urine cells. Cell & Bioscience. 13(1). 88–88. 3 indexed citations
10.
Li, Chenyang, Zhangyan Lyu, Zhipeng Wang, et al.. (2023). The changes of subtype markers between first and second primary breast cancers. Cancer Medicine. 12(12). 13649–13660. 2 indexed citations
11.
Wang, Tao, Jiayi Chen, Yang Jin, et al.. (2022). CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis. PubMed. 3. 22–22. 6 indexed citations
12.
Guo, Jiangtao, Wei Zhao, Hong Zhu, et al.. (2021). MicroRNA-449 targets histone deacetylase 1 to regulate the proliferation, invasion, and apoptosis of synovial fibroblasts in rheumatoid arthritis. Annals of Palliative Medicine. 10(7). 7960–7969. 15 indexed citations
13.
Guo, Jiangtao, Xiaoli Ma, Chunfang Hao, et al.. (2020). Tumor necrosis factor receptor-associated factor 6 (TRAF6) inhibition modulates bone loss and matrix metalloproteinase expression levels in collagen-induced rheumatoid arthritis rat. Annals of Palliative Medicine. 9(6). 4017–4028. 4 indexed citations
14.
Jia, Yongsheng, et al.. (2020). A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer. Journal of Cancer Research and Therapeutics. 16(5). 1069–1069. 4 indexed citations
15.
Hao, Chunfang, et al.. (2017). ILK promotes cell proliferation in breast cancer cells by activating the PI3K/Akt pathway. Molecular Medicine Reports. 16(4). 5036–5042. 16 indexed citations
16.
Wang, Shuling, Weidong Li, Fang Wang, et al.. (2017). 36 cases adenoid cystic carcinoma of the breast in China: Comparison with matched grade one invasive ductal carcinoma-not otherwise specified. Pathology - Research and Practice. 213(4). 310–315. 8 indexed citations
17.
Guo, Jiangtao, Wei Zhao, Huiying Yang, et al.. (2017). SIRT1 promotes tumor-like invasion of fibroblast-like synoviocytes in rheumatoid arthritis via targeting TIMP1. Oncotarget. 8(51). 88965–88973. 13 indexed citations
18.
Hao, Chunfang, et al.. (2012). The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model. Molecular and Cellular Biochemistry. 367(1-2). 93–102. 6 indexed citations
19.
Hao, Chunfang, Sen Wei, Zhongsheng Tong, et al.. (2012). The effects of RKIP gene expression on the biological characteristics of human triple-negative breast cancer cells in vitro. Tumor Biology. 33(4). 1159–1167. 13 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Beige Zong Breakdown of academic impact, for papers by Bastianina Canu Breakdown of academic impact, for papers by Eirini Biziota Breakdown of academic impact, for papers by Alexander N. Gorelick Breakdown of academic impact, for papers by Huanlei Wu Breakdown of academic impact, for papers by Tomasz Tyszkiewicz Breakdown of academic impact, for papers by Hengyu Lu Breakdown of academic impact, for papers by Ben Staal Breakdown of academic impact, for papers by Woody Han Breakdown of academic impact, for papers by Dionysis Papadatos-Pastos
Rankless by CCL
2026